Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors
Author:
Affiliation:
1. Centre de Recherches, AstraZeneca, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, France
2. Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom
Publisher
American Chemical Society (ACS)
Subject
Organic Chemistry,Drug Discovery,Biochemistry
Link
https://pubs.acs.org/doi/pdf/10.1021/ml400146c
Reference24 articles.
1. NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer
2. Epidermal growth factor receptor: mechanisms of activation and signalling
3. The deaf and the dumb: the biology of ErbB-2 and ErbB-3
4. EGFR Antagonists in Cancer Treatment
Cited by 38 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents;Current Medicinal Chemistry;2024-06-10
2. Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling;Frontiers in Pharmacology;2024-01-10
3. Design, synthesis and biological evaluation of EGFR kinase inhibitors that spans the orthosteric and allosteric sites;Bioorganic & Medicinal Chemistry;2023-12
4. Functional genomics of human clear cell sarcoma: genomic, transcriptomic and chemical biology landscape for clear cell sarcoma;British Journal of Cancer;2023-03-23
5. Utilization of Supervised Machine Learning to Understand Kinase Inhibitor Toxophore Profiles;International Journal of Molecular Sciences;2023-03-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3